Clinical trial · Observational
PRO for Fighting FT in Ovarian Cancer
Patient-Reported Outcome for Fighting Financial Toxicity in Ovarian Cancer
NCT06032975CI-TRIAL-00071282MITO45-ProFFiTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Cohort 1:
- description
- Patients undergoing their first medical treatment for OC (including adjuvant and neo-adjuvant chemotherapy and first-line treatment for advanced in patients not previously treated with adjuvant chemotherapy)
- interventionNames
- Other: Questionnaires
- label
- Cohort 2
- description
- Patients undergoing their second medical treatment for OC (including the second-line treatment for advanced disease and the first-line treatment for advanced disease in patients previously treated with adjuvant CT)
- interventionNames
- Other: Questionnaires
- label
- Cohort 3
- description
- Patients undergoing their third medical treatment for OC (including the third-line treatment for advanced disease and the second-line treatment for advanced disease in patients previously treated with adjuvant CT)
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Written informed consent provided; * Women ≥18 years; * Histologically or citologically confirmed diagnosis of epithelial ovarian, fallopian tube or peritoneal cancer stage IC-IV according to FIGO staging system; * Patients who are close to begin any type of medical treatment against ovarian cancer. Exclusion Criteria: * Major cognitive dysfunction or psychiatric disorders; * Patients with epithelial ovarian, fallopian tube or peritoneal cancer candidate exclusively to follow-up; * Patients who have received more than 4 previous lines of medical treatment (maintenance treatments do not represent a line).
References
Publications (0)
Data not yet available
No reference posted for this study.